Sun H Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7610197/publications.pdf

Version: 2024-02-01

70 5,690 27 69 papers citations h-index 91884

71 71 71 71 8149

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	The steatosisâ€associated fibrosis estimator (SAFE) score: A tool to detect lowâ€risk NAFLD in primary care. Hepatology, 2023, 77, 256-267.	7.3	18
2	Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 230-240.	3.6	24
3	Cardiovascular outcomes associated with prescription of sodiumâ€glucose coâ€transporterâ€2 inhibitors versus dipeptidyl peptidaseâ€4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 928-937.	4.4	2
4	Safety and tolerability of high-dose daily vitamin D3 supplementation in the vitamin D and type 2 diabetes (D2d) study—a randomized trial in persons with prediabetes. European Journal of Clinical Nutrition, 2022, 76, 1117-1124.	2.9	8
5	Effect of a ketogenic diet versus Mediterranean diet on glycated hemoglobin in individuals with prediabetes and type 2 diabetes mellitus: The interventional Keto-Med randomized crossover trial. American Journal of Clinical Nutrition, 2022, 116, 640-652.	4.7	44
6	Effect of the glucagonâ€like peptideâ€1 analogue liraglutide versus placebo treatment on circulating proglucagonâ€derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 489-498.	4.4	14
7	Association of pericardial adipose tissue with left ventricular structure and function: a regionâ€specific effect?. Cardiovascular Diabetology, 2021, 20, 26.	6.8	15
8	Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2767-2778.	3.6	20
9	Adherence to Ketogenic and Mediterranean Study Diets in a Crossover Trial: The Keto–Med Randomized Trial. Nutrients, 2021, 13, 967.	4.1	30
10	Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1201-1209.	4.5	9
11	Statins Are Associated With Increased Insulin Resistance and Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2786-2797.	2.4	49
12	Increasing Mortality Among Patients With Diabetes and Chronic Liver Disease From 2007 to 2017. Clinical Gastroenterology and Hepatology, 2020, 18, 992-994.	4.4	6
13	A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose CotransporterÂ2 Inhibitors (SGLT2i). Cardiology and Therapy, 2020, 9, 219-225.	2.6	6
14	A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes. Endocrine Practice, 2020, 26, 990-996.	2.1	3
15	A Nuanced Relationship Between Prediabetes and Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1906-e1907.	3.6	O
16	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e130-e138.	3.6	22
17	Natural course of fatty liver in 36,195 South Korean adults. Scientific Reports, 2019, 9, 9062.	3.3	4
18	Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 107423.	2.3	2

#	Article	IF	CITATIONS
19	Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 520-530.	27.0	423
20	Longitudinal changes in left ventricular structure and function in patients with type 2 diabetes: Normal weight versus overweight/obesity. Diabetes and Vascular Disease Research, 2019, 16, 450-457.	2.0	4
21	Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study. Journal of Clinical Medicine, 2019, 8, 445.	2.4	11
22	Impact of race/ethnicity on insulin resistance and hypertriglyceridaemia. Diabetes and Vascular Disease Research, 2019, 16, 153-159.	2.0	46
23	Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017. Diabetologia, 2019, 62, 1185-1194.	6.3	23
24	Myths about Insulin Resistance: Tribute to Gerald Reaven. Endocrinology and Metabolism, 2019, 34, 47.	3.0	5
25	Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. New England Journal of Medicine, 2018, 378, 708-718.	27.0	3,433
26	Time From Imaging to Endovascular Reperfusion Predicts Outcome in Acute Stroke. Stroke, 2018, 49, 952-957.	2.0	21
27	Adapting to insulin resistance in obesity: role of insulin secretion and clearance. Diabetologia, 2018, 61, 681-687.	6.3	54
28	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care, 2018, 41, 1590-1599.	8.6	16
29	Racial Differences in Insulin Resistance, Secretion, and Clearance. Diabetes, 2018, 67, .	0.6	1
30	Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea. American Journal of Cardiology, 2017, 119, 1205-1210.	1.6	2
31	Relationship among age, insulin resistance, and blood pressure. Journal of the American Society of Hypertension, 2017, 11, 359-365.e2.	2.3	15
32	Dissecting the relationship between obesity and hyperinsulinemia: Role of insulin secretion and insulin clearance. Obesity, 2017, 25, 378-383.	3.0	33
33	Inflammation in the Prediction of Type 2 Diabetes and Hypertension in Healthy Adults. Archives of Medical Research, 2017, 48, 535-545.	3.3	18
34	Does enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot study. Sleep Medicine, 2016, 22, 57-60.	1.6	11
35	Insulin Clearance: An Underappreciated Modulator of Plasma Insulin Concentration. Journal of Investigative Medicine, 2016, 64, 1162-1165.	1.6	28
36	Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2104-2106.	4.5	1

#	Article	IF	CITATIONS
37	Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. Current Atherosclerosis Reports, 2016, 18, 7.	4.8	2
38	Fast Padé Transform Accelerated CSI for Hyperpolarized MRS. Tomography, 2016, 2, 117-124.	1.8	8
39	Hyperinsulinemia in individuals with obesity: Role of insulin clearance. Obesity, 2015, 23, 2430-2434.	3.0	42
40	Abnormalities of Lipoprotein Concentrations in Obstructive Sleep Apnea Are Related to Insulin Resistance. Sleep, 2015, 38, 793-799.	1.1	24
41	Increased body mass index negatively impacts blastocyst formation rate in normal responders undergoing in vitro fertilization. Journal of Assisted Reproduction and Genetics, 2015, 32, 1299-1304.	2.5	49
42	Usefulness of Fetuin-A to Predict Risk for Cardiovascular Disease Among Patients With Obstructive Sleep Apnea. American Journal of Cardiology, 2015, 116, 219-224.	1.6	6
43	Comparison of the association with sleep apnoea of obesityversusinsulin resistance. European Respiratory Journal, 2015, 46, 1829-1832.	6.7	1
44	Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals. Journal of Clinical Lipidology, 2015, 9, 658-663.	1.5	12
45	Relationship between insulin resistance and amino acids in women and men. Physiological Reports, 2015, 3, e12392.	1.7	43
46	Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Diabetologia, 2014, 57, 455-462.	6.3	32
47	A retrospective cohort study to evaluate the impact of meaningful weight loss on fertility outcomes in an overweight population with infertility. Fertility and Sterility, 2014, 101, 1400-1403.	1.0	69
48	Effect of Salsalate on Insulin Action, Secretion, and Clearance in Nondiabetic, Insulin-Resistant Individuals: A Randomized, Placebo-Controlled Study. Diabetes Care, 2014, 37, 1944-1950.	8.6	29
49	Ability of the plasma concentration ratio of triglyceride/high-density lipoprotein cholesterol to identify increased cardio-metabolic risk in an east Asian population. Diabetes Research and Clinical Practice, 2014, 105, 96-101.	2.8	16
50	C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians. European Heart Journal, 2014, 35, 1809-1816.	2.2	46
51	Beyond fasting plasma glucose: The association between coronary heart disease risk and postprandial glucose, postprandial insulin and insulin resistance in healthy, nondiabetic adults. Metabolism: Clinical and Experimental, 2013, 62, 1223-1226.	3.4	16
52	Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes. Diabetes Care, 2013, 36, 3276-3282.	8.6	78
53	Sex Differences in Insulin Resistance and Cardiovascular Disease Risk. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1716-E1721.	3.6	38
54	Relationship between Insulin Resistance and Coronary Artery Calcium in Young Men and Women. PLoS ONE, 2013, 8, e53316.	2.5	13

#	Article	IF	CITATIONS
55	Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications. International Clinical Psychopharmacology, 2011, 26, 43-47.	1.7	11
56	Interrelationship between Fatty Liver and Insulin Resistance in the Development of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1093-1097.	3.6	114
57	Glucose-Stimulated Insulin Secretion in Gastric Bypass Patients with Hypoglycemic Syndrome: No Evidence for Inappropriate Pancreatic Î ² -cell Function. Obesity Surgery, 2010, 20, 1110-1116.	2.1	18
58	Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. Journal of Psychiatric Research, 2010, 44, 493-498.	3.1	22
59	Utility of Homeostasis Model Assessment of \hat{l}^2 -Cell Function in Predicting Diabetes in 12,924 Healthy Koreans. Diabetes Care, 2010, 33, 200-202.	8.6	35
60	Obesity and Insulin Resistance: An Ongoing Saga. Diabetes, 2010, 59, 2105-2106.	0.6	23
61	Effect of moderate alcoholic beverage consumption on insulin sensitivity in insulin-resistant, nondiabetic individuals. Metabolism: Clinical and Experimental, 2009, 58, 387-392.	3.4	36
62	Plasma Glucose and Insulin Regulation Is Abnormal Following Gastric Bypass Surgery with or Without Neuroglycopenia. Obesity Surgery, 2009, 19, 1550-1556.	2.1	51
63	Isolated Impaired Fasting Glucose and Peripheral Insulin Sensitivity. Diabetes Care, 2008, 31, 347-352.	8.6	43
64	Insulin Resistance and Hyperinsulinemia. Diabetes Care, 2008, 31, 1433-1438.	8.6	66
65	Relationship Among Alcohol, Body Weight, and Cardiovascular Risk Factors in 27,030 Korean Men. Diabetes Care, 2007, 30, 2690-2694.	8.6	44
66	Metabolic Impact of Switching Antipsychotic Therapy to Aripiprazole After Weight Gain. Journal of Clinical Psychopharmacology, 2007, 27, 365-368.	1.4	39
67	Comparison of the 1997 and 2003 American Diabetes Association Classification of Impaired Fasting Glucose. Journal of the American College of Cardiology, 2006, 48, 293-297.	2.8	37
68	Rosiglitazone Reduces Glucose-Stimulated Insulin Secretion Rate and Increases Insulin Clearance in Nondiabetic, Insulin-Resistant Individuals. Diabetes, 2005, 54, 2447-2452.	0.6	41
69	Impact of Degree of Obesity on Surrogate Estimates of Insulin Resistance. Diabetes Care, 2004, 27, 1998-2002.	8.6	129
70	The metabolic syndrome: one step forward, two steps back. Diabetes and Vascular Disease Research, 2004, 1, 68-75.	2.0	36